Atherosclerosis development in apolipoprotein E-null mice deficient for CD69

Cardiovascular Research

Volumn 81, Issue 1, 2009, Pages 197-205

  Gómez, Manuel ^a   Sanz González, Silvia M ^b,d   Nabah, Yafa Naim Abu ^b   Lamana, Amalia ^a   Sánchez Madrid, Francisco ^a,c   Andrés, Vicente ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Apolipoprotein E null mouse; Atherosclerosis; CD69

Indexed keywords

APOLIPOPROTEIN E; CD69 ANTIGEN; CELL SURFACE RECEPTOR; CHOLESTEROL OXIDASE; COLLAGEN; GAMMA INTERFERON; INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CELL SURFACE; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DEPLETION; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE DISRUPTION; GENETIC MANIPULATION; HOMEOSTASIS; INFLAMMATORY DISEASE; INTERFERON PRODUCTION; LEUKOCYTE ACTIVATION; LIPID COMPOSITION; LIPID DIET; MALE; MENTAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; DISEASE MODELS, ANIMAL; INTERFERON-GAMMA; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 57749192648     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn227     Document Type: Article

References (40)

1. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-S420.
3. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8:1257-1262.
4. Andrés V. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential. Cardiovasc Res 2004;63:11-21.
5. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995;25(Suppl. 2):S9-S12.
6. Burke-Gaffney A, Brooks AV, Bogle RG. Regulation of chemokine expression in atherosclerosis. Vascul Pharmacol 2002;38:283-292.
7. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A et al. Innate and acquired immunity in atherogenesis. Nat Med 2002;8:1218-1226.
8. Greaves DR, Channon KM. Inflammation and immune responses in atherosclerosis. Trends Immunol 2002;23:535-541.
9. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519.
10. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001;104:503-516.
11. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-291.
12. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006;26:2421-2432.
13. Hara T, Jung LK, Bjorndahl JM, Fu SM. Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o- tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med 1986;164:1988-2005.
14. Cosulich ME, Rubartelli A, Risso A, Cozzolino F, Bargellesi A. Functional characterization of an antigen involved in an early step of T-cell activation. Proc Natl Acad Sci USA 1987;84:4205-4209.
15. Cebrian M, Yague E, Rincon M, Lopez-Botet M, de Landazuri MO, Sanchez-Madrid F. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J Exp Med 1988;168:1621-1637.
16. Sancho D, Yañez-Mo M, Tejedor R, Sánchez-Madrid F. Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen- 1/intercellular adhesion molecule-1 and interleukin-15. Blood 1999;93:886-896.
17. Sánchez-Mateos P, Cebrian M, Acevedo A, López-Botet M, Ortiz de Landazuri M, Sánchez-Madrid F. Expression of a gp33/27,000 MW activation inducer molecule (AIM) on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies. Immunology 1989;68:72-79.
18. Laffon A, Garcia-Vicuna R, Humbria A, Postigo AA, Corbi AL, de Landazuri MO et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J Clin Invest 1991;88:546-552.
19. Garcia-Monzon C, Moreno-Otero R, Pajares JM, Garcia-Sanchez A, Lopez-Botet M, de Landazuri MO et al. Expression of a novel activation antigen on intrahepatic CD8+ T lymphocytes in viral chronic active hepatitis. Gastroenterology 1990;98:1029-1035.
20. Marazuela M, Postigo AA, Acevedo A, Díaz-González F, Sánchez-Madrid F, de Landazuri MO. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. Eur J Immunol 1994;24:2483-2490.
21. Crispin JC, Martinez A, de Pablo P, Velasquillo C, Alcocer-Varela J. Participation of the CD69 antigen in the T-cell activation process of patients with systemic lupus erythematosus. Scand J Immunol 1998;48:196- 200.
22. Gessl A, Waldhausl W. Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing. J Clin Endocrinol Metab 1998;83:2204-2209.
23. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989;143:1123-1128.
24. Lauzurica P, Sancho D, Torres M, Albella B, Marazuela M, Merino T et al. Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. Blood 2000;95:2312-2320.
25. Sancho D, Gómez M, Viedma F, Esplugues E, Gordon-Alonso M, García-Lopez MA et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. J Clin Invest 2003;112:872-882.
26. Esplugues E, Sancho D, Vega-Ramos J, Martinez C, Syrbe U, Hamann A et al. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med 2003;197:1093-1106.
27. Sancho D, Gómez M, Sánchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005;26:136-140.
28. Sancho D, Gómez M, Martínez Del Hoyo G, Lamana A, Esplugues E, Lauzurica P et al. CD69 targeting differentially affects the course of collagen-induced arthritis. J Leukoc Biol 2006;80:1233-1241.
29. Khallou-Laschet J, Caligiuri G, Groyer E, Tupin E, Gaston AT, Poirier B et al. The proatherogenic role of T cells requires cell division and is dependent on the stage of the disease. Arterioscler Thromb Vasc Biol 2006;26:353-358.
30. González-Navarro H, Nong Z, Amar MJ, Shamburek RD, Najib-Fruchart J, Paigen BJ et al. The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice. J Biol Chem 2004;279:45312-45321.
31. Kip1 protects against diet-induced atherosclerosis. FASEB J 2001;15:1989-1995.
32. Kip1 in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood 2004;103:158-161.
33. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004;24:1006-1014.
34. Marzio R, Jirillo E, Ransijn A, Mauel J, Corradin SB. Expression and function of the early activation antigen CD69 in murine macrophages. J Leukoc Biol 1997;62:349-355.
35. Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1997;94:4642-4646.
36. -/- mice. J Clin Invest 1997;100:1575-1580.
37. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997;61:1861-1878.
38. Harvey EJ, Ramji DP. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res 2005;67:11-20.
39. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999;85:e17-e24.
40. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847-2853.